Navigation Links
Valensa Expands Astaxanthin Extraction Capacity
Date:2/14/2008

Growing Demand for High-Quality Finished Product that Meets Regulatory & Health Issues and New Strategic Alliance Create Conditions for Expansion

ORLANDO, Fla., Feb. 14 /PRNewswire/ -- Valensa International announced today that it has increased its capacity for the extraction of Haematococcus pluvialis for the manufacture of finished all-natural astaxanthin. The move was made in light of recently growing demand for a high-quality astaxanthin in North America, Asia and Europe that is both pesticide-free and allergen-free - two conditions that are only possible with select raw material sources and extraction facilities. In addition to market demand, a recently formed Strategic Alliance with Cyanotech Corporation (Kona, HI), where Valensa provides extraction services of raw material provided by Cyanotech, will require increased capacity to facilitate orderly growth of supply for the market and increased uptake of Valensa's own ZANTHIN(R) natural astaxanthin brand. The capacity expansion will be approximately 20% and will be achieved primarily through manufacturing efficiencies and de-bottlenecking its facilities in Eustis, Florida, USA. The expansion will include new facilities for screening biomass against the presence of pesticides. Astaxanthin products extracted at Valensa's Eustis facility will be certified pesticide- and allergen-free.

According to Dr. Rudi Moerck, President of Valensa, high-quality astaxanthin biomass and strict quality control in manufacturing are the two key elements for creating a finished astaxanthin product that meets or exceeds the quality and regulatory requirements of world markets. "There is growing interest and excitement about the potential of astaxanthin - the world's most potent antioxidant with clinical trial data indicating support in areas such as eye health, neurological health, immune support, inflammation reduction and skin health. Recently, the demand for a high-quality, pesticide-free source of the product has outstripped supply. The Strategic Alliance that we have formed with Cyanotech Corporation and our move to increase extraction capacity will help meet market requirements for this growing demand," he said. "Valensa has provided extraction services to Cyanotech for some time now and we were impressed by their biomass purity and pesticide-free profile," he said. "Our company has previously qualified a number of astaxanthin biomass sources, but product purity and overall product integrity led us to choose Cyanotech as our principal algae biomass supplier." Valensa's ZANTHIN(R) natural astaxanthin product has been marketed in the United States for over a decade and was the first astaxanthin extract to have Novel Foods approval in the European Union in July 2004. "These approvals require a pesticide-free, solvent-free and allergen-free astaxanthin. By qualifying our suppliers and screening our raw materials, through the use of supercritical carbon dioxide extraction technology and through our superior quality management, we are uniquely positioned to deliver the astaxanthin products required by world markets," said Dr. Moerck.

For further information, contact:

Dr. Rudi Moerck, President

Voice: 352-357-2004

Fax: 352-483-2095

http://www.valensa.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Valensa International
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Progen Expands Drug Development Pipeline Through Acquisition of CellGate
2. Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand
3. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
4. PPD Expands Global Central Lab Services into China
5. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
6. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
7. Ventria Expands Team and Hires Kansan as Director of Bioprocessing Operations
8. Symmetry Medical Expands Board of Directors
9. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
10. Observant LLC Expands Senior Management Team
11. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 25, 2017 , ... Throughout this webinar, participants ... how process development and economic goals were achieved in both industry and academic ... bioreactor system, along with techniques for scaling production of mesenchymal stem cells (MSCs) ...
(Date:5/24/2017)... ... May 24, 2017 , ... Benchworks announced that ... of the Healthcare Businesswomen’s Association (HBA). Nominated by chapter president Donna ... meets in person once each quarter and holds monthly conference calls. In addition, ...
(Date:5/24/2017)... ... 23, 2017 , ... Federal funding for basic and applied scientific research — ... and other vital technologies — deserves continued support, say leaders of SPIE, the ... today in responding to the President’s budget request for Fiscal Year 2018. , The ...
(Date:5/23/2017)... ... May 23, 2017 , ... Firmex today ... makes it easy for organizations to send and gather large files and confidential ... or email file size limitations. , Using the same market-tested infrastructure as ...
Breaking Biology Technology:
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
Breaking Biology News(10 mins):